ストックスクリーナーアプリを入手
0.9999
1.49%
-0.0051
前日終値:
$1.005
開ける：
$1
24時間の取引高:
20,779
Relative Volume:
0.01
時価総額：
$3.42M
収益：
-
当期純損益:
$-13.47M
株価収益率:
-0.0257
EPS:
-38.9215
ネットキャッシュフロー:
$-8.38M
1週間 パフォーマンス:
-10.00%
1か月 パフォーマンス:
-25.56%
6か月 パフォーマンス:
-79.38%
1年 パフォーマンス:
-97.92%
1日の値動き範囲:
$0.98
$1.00
1週間の範囲:
$0.98
$1.12
52週間の値動き範囲:
$0.98
$85.80
Artelo Biosciences Inc Stock (ARTL) Company Profile
名前
Artelo Biosciences Inc
セクター
電話
858-925-7049
住所
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Compare ARTL vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
0.98 | 3.50M | 0 | -13.47M | -8.38M | -38.92 |
VRTX
Vertex Pharmaceuticals Inc
|
514.30 | 132.55B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.73 | 70.90B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.19 | 57.21B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.23 | 42.94B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.04 | 40.49B | 742.00K | -1.37B | -1.07B | -7.0731 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-08 | アップグレード | D. Boral Capital | Hold → Buy |
| 2021-02-12 | 開始されました | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc (ARTL) 最新ニュース
Artelo Biosciences Company Profile & Introduction - Moomoo
Artelo Biosciences regains Nasdaq listing compliance - Investing.com
ARTELO BIOSCIENCES INC (ARTL) Stock Chart - ChartMill
ARTLArtelo Biosciences Inc Latest SEC Filings - Finviz
Artelo Biosciences (ARTL) Reveals Positive Preclinical Data in N - GuruFocus
Artelo Biosciences Announces New Data Support - Moomoo
Artelo's ART26.12 eased spinal cord injury pain in mice - Stock Titan
Artelo presents research on FABP5 inhibitor ART26.12 - Investing.com UK
Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026 - The Manila Times
Artelo Biosciences Reports Multi-Omics Findings Highlighting Linoleic Acid Link in ART26.12 FABP5 Inhibition - Quiver Quantitative
Artelo presents phase 1 data for FABP5 inhibitor ART26.12 - Investing.com UK
Artelo Biosciences Presents Clinical And Biomarker Data Supportive Of The Development Of ART26.12 And Follow-On FABP5 Inhibitors - marketscreener.com
Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026 - The Manila Times
Artelo presents phase 1 data for FABP5 inhibitor ART26.12 By Investing.com - Investing.com Canada
Artelo Biosciences Reports Positive First-in-Human ART26.12 Safety and Pharmacokinetic Results, Advances AI-Enabled Biomarker Research - Quiver Quantitative
Artelo’s first-in-human FABP5 inhibitor shows tolerability, biomarker signals - Stock Titan
Artelo Biosciences Inc Actuals & Estimates (NASDAQ:ARTL) - TradingView
Artelo Biosciences Inc (ARTL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Why JOYY shares are trading higher by 12%; here are 20 stocks moving premarket - MSN
Artelo Biosciences (ARTL) asks shareholders to approve >20% issuance to Square Gate - Stock Titan
Artelo Biosciences Inc (ARTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ARTL Q4 2025 Earnings: EPS Surprise of 97.5% as Quarterly Losses Narrow SharplyEarnings Whisper Number - dars.gov.et
Artelo Biosciences Inc (ARTL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Artelo Biosciences Inc (ARTL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Artelo Biosciences Inc (ARTL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Artelo Biosciences Inc (ARTL) Institutional Confidence - TradingKey
Artelo Biosciences Expands Horizons with Strategic Trials - timothysykes.com
Artelo Biosciences Targets Glaucoma Market with Strategic Drug Development - timothysykes.com
ARTL Q4 2025 Earnings: EPS Surprise of 97.5% Beats EstimatesGuidance Upgrade Report - newsline.com
Artelo Biosciences Surges with Groundbreaking Glaucoma Study Announcement - timothysykes.com
Artelo Biosciences (ARTL) Rebounds 3%: Key Support Holds Amid Biotech Sector VolatilityValue Area High - newsline.com
Artelo Biosciences discloses positive ART26.12 metabolite profile - grafa.com
Artelo Biosciences reports favorable metabolism... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success - The Manila Times
Artelo Biosciences, Inc. - MLQ.ai
[ARS] ARTELO BIOSCIENCES, INC. SEC Filing - Stock Titan
Artelo Biosciences (NASDAQ: ARTL) proxy seeks large boost in authorized shares - Stock Titan
ARTL Stock Price, Quote & Chart | ARTELO BIOSCIENCES INC (NASDAQ:ARTL) - ChartMill
Artelo Biosciences Q4 2025 Earnings: Massive EPS Beat Despite Zero Revenue, Stock DeclinesEstimate Accuracy - newsline.com
Artelo Biosciences Launches Flexible At-The-Market Offering - The Globe and Mail
Artelo Biosciences, Inc. Announces At The Market Offering Agreement With H.C. Wainwright & Co - Minichart
Artelo Biosciences (ARTL) Gains 7.35%: Biotech Stock Tests Resistance Near $1.53Combination Correction - newsline.com
Artelo Biosciences stock tumbles on $6.5M share offering - Investing.com
Artelo Biosciences Launches $6.53 Million ATM Equity Program With H.C. Wainwright - TradingView
[8-K] ARTELO BIOSCIENCES, INC. Reports Material Event - Stock Titan
Dow Jumps Over 300 Points; Dick's Sporting Shares Fall After Q1 Results - Benzinga
Artelo Biosciences stock tumbles on $6.5M share offering By Investing.com - Investing.com Nigeria
Artelo Biosciences to offer up to $6.53 million in common stock via H.C. Wainwright - marketscreener.com
Artelo Biosciences To Offer Up To $6.53 Million In Common Stock Via H.C. Wainwright - TradingView
Artelo Biosciences (ARTL) asks shareholders to approve 500M-share authorization - Stock Titan
Artelo Biosciences (ARTL) launches $6.53M at-the-market program with HCW - Stock Titan
Artelo Biosciences Inc (ARTL) 財務データ
収益
当期純利益
現金流量
EPS
1.09%
5.65%
大文字化:
|
ボリューム (24 時間):